Why the study?
Does immunolabelling with antibodies to nNOS improve the diagnosis of Becker muscular dystrophy in patients with equivocal dystrophin labelling?
Does immunolabelling with antibodies to nNOS improve the diagnosis of Becker muscular dystrophy in patients with equivocal dystrophin labelling?
Absence of sarcolemmal nNOS can serve as a sensitive diagnostic marker for Becker muscular dystrophy in cases where dystrophin immunolabelling is equivocal.
No takes yet. Share an insight, caveat, or question.
nNOS immunolabelling may aid BMD diagnosis with equivocal dystrophin; leaves open validation in larger cohorts before practice change.
Torelli et al. (2004) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: